FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC By Ogkologos - March 18, 2026 246 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Beamion LUNG-1 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR EMA Recommends Extension of Indications for Selumetinib October 9, 2025 FDA Approves Belumosudil to Treat Chronic Graft-Versus-Host Disease August 18, 2021 The award-winning team transforming breast cancer treatment April 10, 2022 Not Old Enough for Breast Cancer, She Demanded a Mammogram Anyway... September 16, 2020 Load more HOT NEWS Επικοινωνία Facing Crisis After Crisis During Cancer: How to Cope Atezolizumab Approved for Some Patients with Triple-Negative Breast Cancer Feeling the pull: Using magnetic drug targeting to improve chemotherapy in...
